Elesclomol (STA-4783) is a potent inhibitor of topoisomerase II

被引：1
|
作者：
Wu, Xing [1 ]
Yalowich, Jack C. [2 ]
Hasinoff, Brian B. [1 ]
机构：
[1] Univ Manitoba, Winnipeg, MB, Canada
[2] Ohio State Univ, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1757
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1757
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Integrated safety analysis of elesclomol (formerly STA-4783) co-administered with paclitaxel
    Agarwala, S. S.
    Haddad, J.
    Jacobson, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] INTEGRATED SAFETY ANALYSIS OF THE OXIDATIVE STRESS INDUCER ELESCLOMOL (FORMERLY STA-4783) CO-ADMINISTERED WITH PACLITAXEL
    Agarwala, S. S.
    Haddad, J.
    Jacobson, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [3] Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy
    Gonzalez, R.
    Lawson, D. H.
    Weber, R. W.
    Hutchins, L. F.
    Anderson, C. M.
    Williams, K. N.
    Kong, S.
    Jacobson, E.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] ELESCLOMOL (FORMERLY STA-4783) AND PACLITAXEL IN STAGE IV METASTATIC MELANOMA (MM): 2-YEAR OVERALL SURVIVAL (OS)
    O'Day, S. J.
    Gonzalez, R.
    Weber, R.
    Hutchins, L. F.
    Anderson, C. M.
    Williams, K. N.
    Kong, S.
    Jacobson, E.
    Lawson, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 240 - 240
  • [5] 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM)
    Lawson, D. H.
    Gonzalez, R.
    Weber, R. W.
    Hutchins, L. F.
    Anderson, C. M.
    Williams, K. N.
    Kong, S.
    Jacobson, E.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Transient downregulation of NR4A1 leads to impaired osteoblast differentiation through the TGF-ss pathway, and Elesclomol (STA-4783) rescues this phenotype
    Muthurangan, Manikandan
    Elsafadi, Mona
    Siyal, Abdulaziz
    Kaimkhani, Zahid Ali
    Umrani, Arbila
    AlMuraikhi, Nihal A.
    Alfayez, Musaad
    Abdelhady, Essam Eldin
    Alqahtani, Hamad
    Basavarajappa, Santhosh
    Aboul-Soud, Mourad A. M.
    Mahmood, Amer
    CELL BIOCHEMISTRY AND FUNCTION, 2023, 41 (05) : 590 - 598
  • [7] Drug evaluation: STA-4783 - enhancing taxane efficacy by induction of Hsp70
    Gehrmann, M
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (06) : 574 - 580
  • [8] Synthesis and biological activities of STA-4783:: A novel small molecule Taxol® enhancer.
    Sun, LJ
    Chen, SJ
    Koya, K
    Xia, ZQ
    Tatsuta, N
    Korbut, T
    Du, ZJ
    Liang, GQ
    Zhou, D
    Ono, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U26 - U26
  • [9] Concurrent chemoradiation therapy with the oxidative stress inducer STA-4783 in mouse xenograft tumor models
    Foley, K. P.
    Mihalek, R.
    Korbut, T.
    Sang, J.
    Song, W.
    Zhang, C.
    Kirshner, J.
    Du, Z.
    Bertin, J.
    Barsoum, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S593 - S594
  • [10] Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors
    Berkenblit, Anna
    Eder, Joseph P., Jr.
    Ryan, David P.
    Seiden, Michael V.
    Tatsuta, Noriaki
    Sherman, Matthew L.
    Dahl, Thomas A.
    Dezube, Bruce J.
    Supko, Jeffrey G.
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 584 - 590
12345